{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Once+Weekly&page=14", "query": { "intervention": "Placebo Once Weekly", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 897, "total_pages": 90, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Once+Weekly&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Once+Weekly&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T00:46:42.219Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05407324", "title": "Dazucorilant in Patients With Amyotrophic Lateral Sclerosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Amyotrophic Lateral Sclerosis" ], "interventions": [ { "name": "Dazucorilant 300 mg", "type": "DRUG" }, { "name": "Dazucorilant 150 mg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Dazucorilant", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Corcept Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 279, "start_date": "2022-11-15", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-11-12T00:46:42.219Z", "location_count": 4, "location_summary": "Phoenix, Arizona • San Francisco, California • Neptune City, New Jersey + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Neptune City", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05407324" }, { "nct_id": "NCT02376790", "title": "Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Etanercept", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Placebo to Etanercept", "type": "DRUG" }, { "name": "Placebo to Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 851, "start_date": "2015-03-03", "completion_date": "2018-07-06", "has_results": true, "last_update_posted_date": "2022-09-21", "last_synced_at": "2026-11-12T00:46:42.219Z", "location_count": 55, "location_summary": "Tuscaloosa, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02376790" }, { "nct_id": "NCT07220642", "title": "Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Obesity", "Overweight" ], "interventions": [ { "name": "Cagrilintide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2025-11-05", "completion_date": "2027-06-29", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-11-12T00:46:42.219Z", "location_count": 9, "location_summary": "Walnut Creek, California • Aurora, Colorado • Orlando, Florida + 6 more", "locations": [ { "city": "Walnut Creek", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Oviedo", "state": "Florida" }, { "city": "Oak Park", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07220642" }, { "nct_id": "NCT06077864", "title": "A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "survodutide", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5530, "start_date": "2023-11-20", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-10-29", "last_synced_at": "2026-11-12T00:46:42.219Z", "location_count": 153, "location_summary": "Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 135 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06077864" }, { "nct_id": "NCT04564547", "title": "Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Islatravir", "type": "DRUG" }, { "name": "Ulonivirine", "type": "DRUG" }, { "name": "BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo to ISL", "type": "DRUG" }, { "name": "Placebo to Ulonivirine", "type": "DRUG" }, { "name": "Placebo to BIC/FTC/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2021-03-09", "completion_date": "2025-01-30", "has_results": true, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-11-12T00:46:42.219Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Los Angeles, California • Ft. Pierce, Florida + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04564547" }, { "nct_id": "NCT02211209", "title": "The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Familial Chylomicronemia Syndrome" ], "interventions": [ { "name": "Volanesorsen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2014-12", "completion_date": "2017-03-28", "has_results": true, "last_update_posted_date": "2022-04-13", "last_synced_at": "2026-11-12T00:46:42.219Z", "location_count": 11, "location_summary": "Encinitas, California • San Francisco, California • Kansas City, Kansas + 8 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02211209" }, { "nct_id": "NCT01236404", "title": "Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)", "type": "DRUG" }, { "name": "Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PhaseBio Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 80, "start_date": "2010-11", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2013-05-21", "last_synced_at": "2026-11-12T00:46:42.219Z", "location_count": 3, "location_summary": "Walnut Creek, California • Saint Paul, Minnesota • Renton, Washington", "locations": [ { "city": "Walnut Creek", "state": "California" }, { "city": "Saint Paul", "state": "Minnesota" }, { "city": "Renton", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01236404" }, { "nct_id": "NCT06388187", "title": "A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "Cagrilintide", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2024-06-24", "completion_date": "2026-04-22", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-11-12T00:46:42.219Z", "location_count": 7, "location_summary": "Costa Mesa, California • Plantation, Florida • Indianapolis, Indiana + 4 more", "locations": [ { "city": "Costa Mesa", "state": "California" }, { "city": "Plantation", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Wilmington", "state": "North Carolina" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06388187" }, { "nct_id": "NCT06714955", "title": "Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-diabetic Overweight or Obese" ], "interventions": [ { "name": "Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.", "type": "DRUG" }, { "name": "Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.", "type": "DRUG" }, { "name": "Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BrightGene Bio-Medical Technology Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2024-10-21", "completion_date": "2025-03-03", "has_results": false, "last_update_posted_date": "2025-09-22", "last_synced_at": "2026-11-12T00:46:42.219Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06714955" }, { "nct_id": "NCT03840616", "title": "Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Vulvovaginal Candidiasis" ], "interventions": [ { "name": "Oteseconazole (VT-1161) 150mg capsule", "type": "DRUG" }, { "name": "Fluconazole 150mg capsule", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mycovia Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "FEMALE", "summary": "12 Years and older · Female only" }, "enrollment_count": 219, "start_date": "2019-03-13", "completion_date": "2020-12-02", "has_results": true, "last_update_posted_date": "2022-02-04", "last_synced_at": "2026-11-12T00:46:42.219Z", "location_count": 33, "location_summary": "Tucson, Arizona • Encino, California • Los Angeles, California + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Encino", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03840616" } ] }